[Form 4] Arteris, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Arteris, Inc. (AIP) insider Form 4 summary: The company's Chief Operating Officer, Laurent R. Moll, reported multiple sales of common stock in early September 2025 executed pursuant to a 10b5-1 trading plan adopted March 12, 2025. On 09/05/2025 she sold 4,698 shares at a weighted average price of $8.8045, reducing her beneficial ownership to 394,681 shares. On 09/08/2025 she sold 8,129 shares at a weighted average price of $8.7434, reducing beneficial ownership to 386,552 shares. On 09/09/2025 she sold 151 shares at $8.61, leaving 386,401 shares beneficially owned. The Form 4 was signed by an attorney-in-fact.

Positive

• Trades executed under a 10b5-1 plan, which provides an affirmative defense under Rule 10b5-1 and supports compliance with insider trading rules
• Detailed pricing disclosure with weighted average sale prices and an offer to provide per-trade price breakdowns upon request
• Reporting person remains a substantial holder with 386,401 shares beneficially owned after the reported sales

Negative

• Reported reduction in beneficial ownership totaling 12,978 shares sold across three transactions
• Sales over consecutive days (09/05/2025–09/09/2025) which could attract investor attention despite being under a trading plan

Insights

Financial Analyst

TL;DR: Insider sales under a 10b5-1 plan reduced the COO's holdings by 13,0?78 shares over three days; the transactions are routine disclosures.

The filings show structured sales executed under a pre-established 10b5-1 trading plan, indicating the reporting person did not trade opportunistically on undisclosed events within the plan's parameters. Total disclosed disposals equal 12,978 shares across 09/05/2025–09/09/2025 at weighted average prices around $8.61–$8.8045, leaving 386,401 shares beneficially owned. From a market-impact perspective these are modest volumes relative to company-wide float (float not provided), so the sales are informative but not necessarily material to valuation on their own.

Compliance/Risk Analyst

TL;DR: Transactions documented under a 10b5-1 plan and signed by attorney-in-fact comply with standard disclosure rules.

The Form 4 explicitly notes the trades were pursuant to a 10b5-1 plan adopted March 12, 2025, and includes weighted-average price disclosures and an offer to provide per-trade pricing details. The signature by an attorney-in-fact and the inclusion of explanatory footnotes reflect attention to SEC reporting requirements. No indications of amendments or corrective disclosure are present in the provided content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moll Laurent R

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CA 95008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		S(1)		4,698	D	$8.8045(2)	394,681	D
Common Stock	09/08/2025		S(1)		8,129	D	$8.7434(3)	386,552	D
Common Stock	09/09/2025		S(1)		151	D	$8.61	386,401	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 12, 2025.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.69 to $8.93 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.54 to $8.97 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for Moll Laurent R	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did the Arteris (AIP) insider report on Form 4?

The COO reported three sales: 4,698 shares on 09/05/2025 at a weighted average $8.8045, 8,129 shares on 09/08/2025 at $8.7434 weighted average, and 151 shares on 09/09/2025 at $8.61.

Were the Arteris (AIP) insider trades part of a pre-arranged plan?

Yes. The Form 4 states the transactions were made pursuant to a 10b5-1 trading plan adopted by the reporting person on March 12, 2025.

How many Arteris (AIP) shares does the reporting person own after these transactions?

Following the reported sales the reporting person beneficially owned 386,401 shares.

Who signed the Form 4 for the Arteris (AIP) reporting person?

The Form 4 was signed by Paul Alpern as Attorney-in-Fact for Laurent R. Moll on 09/09/2025.

Are detailed per-trade prices for the Arteris (AIP) sales available in the filing?

The filing provides weighted average price ranges and states the reporting person will provide full per-trade price details to the issuer, security holders, or SEC staff upon request.